Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ISAL 2019 | NOX2: a potential immune checkpoint for inhibition in AML

Anna Martner • 25 Feb 2019
ISAL 2019
Acute Myeloid Leukemia Leukemia Checkpoint inhibitors

Myeloid cell NADPH oxidase isoform 2 (NOX2) generates ROS, and recent research indicates that it is a targetable immune checkpoint in cancer. Here, Anna Martner, PhD, of the University of Gothenburg, Gothenburg, Sweden, discusses her group’s recent research into NOX2 inhibitors in KRAS-induced murine models of myeloproliferative disease.

More from Anna Martner

Histamine dihydrochloride and IL-2 for AML: impacts for relapse risk and survival
1:50
Histamine dihydrochloride and IL-2 for AML: impacts for relapse risk and survival
Anna Martner • 25 Feb 2019
What are the advantages of using histamine dihydrochloride together with immunotherapy?
1:50
What are the advantages of using histamine dihydrochloride together with immunotherapy?
Anna Martner • 24 Feb 2017
Biomarkers for acute myeloid leukemia (AML) – lessons from IL-2 immunotherapy with HDC
6:18
Biomarkers for acute myeloid leukemia (AML) – lessons from IL-2 immunotherapy with HDC
Anna Martner • 24 Feb 2017

Related Videos

cAMeLot-2: Phase III trial of bleximenib + venetoclax + azacitidine in AML with KMT2A/NPM1 mutations
1:10
cAMeLot-2: Phase III trial of bleximenib + venetoclax + azacitidine in AML with KMT2A/NPM1 mutations
Anna Martner • 24 Nov 2025
Single-agent SC blinatumomab in R/R B-ALL: Phase I/II efficacy results with extended follow-up
1:16
Single-agent SC blinatumomab in R/R B-ALL: Phase I/II efficacy results with extended follow-up
Anna Martner • 24 Nov 2025
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
Anna Martner • 6 Dec 2025
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
2:20
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
Anna Martner • 6 Dec 2025
The content of VJHemOnc is intended for healthcare professionals